Darunavir (TMC114, Prezista)

Overview | News | Research

Overview

Prescribing Information for Darunavir (TMC114, Prezista) (PDF) (April 2013)
From Janssen Pharmaceuticals, Inc.
An Interview With Cal Cohen, M.D., a Lead Investigator of the Darunavir (TMC114, Prezista) POWER Trials (June 28, 2006)
Dr. Cohen discusses TMC114's uses, adverse effects and other considerations.
Prezista Approval (June 23, 2006)
From U.S. Food and Drug Administration

News

Prezista (Darunavir) Labeling Changes (April 25, 2013)
From U.S. Food and Drug Administration
Once-Daily Option for Pediatric Use of Prezista (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Prezista (Darunavir) Label Change -- Drug Interaction Information (March 1, 2013)
From U.S. Food and Drug Administration
The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors (November 18, 2012)
From Journal Watch
Much More Than Just Following Your Doctor's Orders (July 12, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
FDA Approve Pediatric Dose for Darunavir (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Updated Information About Prezista (Darunavir): Oral Suspension and Labeling Changes (December 20, 2011)
From U.S. Food and Drug Administration
Gilead and Tibotec Agree on New Single-Tablet Regimen (November 23, 2011)
In Positively Aware, from Test Positive Aware Network
Gilead and J&J Expand HIV Cocktail Partnership (November 16, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Tibotec and Gilead Team Up to Develop Prezista/Cobicistat Combo (July 5, 2011)
From Test Positive Aware Network

VIEW ALL ARTICLES

Research

Clinical Trials Using Darunavir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Clinical Trials Using TMC125 (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Coformulated Darunavir/Cobicistat: An Alternative to Separate Ritonavir Boosting (May/June 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Resistance to Darunavir Falling Since Approval of the Protease Inhibitor in 2006 (March 11, 2013)
From National AIDS Treatment Advocacy Project
Darunavir/Ritonavir and Etravirine as a Prevention Method Is Biologically Plausible (Summer 2012)
To read PDF, click here.
In Being Alive Newsletter, from Being Alive
Darunavir Use During Pregnancy (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Top 10 HIV/AIDS-Related Clinical Developments of 2011 (December 1, 2011)
David Alain Wohl, M.D., on HIV treatment as prevention; the dawning of pre-exposure prophylaxis (PrEP), but with women absent; the concept of "viremia copy-years"; the impact of race and gender on HIV treatment outcomes; setbacks for two treatment approaches involving Isentress; new hepatitis C therapies; a new once-daily HIV pill; the rising rates of HIV among black MSM; and what comes after "test and treat."
From TheBody.com
Paediatric Antiretroviral Pipeline: Darunavir and Raltegravir (July/August 2011)
In HIV Treatment Bulletin, from HIV i-Base
Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy (July/August 2011)
To read PDF, click here.
Another NRTI-Sparing Regimen Does Well in Treatment-Naive Patients (July 25, 2011)
From aidsmap.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Cardiovascular Risk Management in HIV Care: Facing Reality
	Scientists Crack HIV's Coating
	Enough With the HIV Treatment Cascade Research, Let's Do Something About It Already: A Blog Entry by Lisa Fitzpatrick, M.D., M.P.H.
	New Danish Results Spark Interest for Future HIV Cure Research
	HIV Eradication Moves One Small Step Closer as Stem Cell Transplant Findings Titillate
	Liquid Injectable Silicone Effective, Safe for Treating HIV Patients With Facial Lipoatrophy: Study

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.